[Federal Register: May 28, 2004 (Volume 69, Number 104)]
[Notices]
[Page 30684]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28my04-67]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Methods for Producing Biliverdin
Michael L. Pendrak, David D. Roberts (NCI)
U.S. Provisional Application No. 60/554,369 filed 19 Mar 2004 (DHHS
Reference No. E-040-2004/0-US-01)
Licensing Contact: Michael Ambrose; 301/594-6565;
ambrosem@mail.nih.gov.
This invention details methods of use and composition of matter for
preparing biliverdin. Biliverdin has been shown to have cytoprotective
properties similar to bilirubin and can be used in the treatment of
cardiovascular diseases, cancer, organ transplantation and other
indications where inflammation occurs.
Incubating bilirubin with a bilirubin oxidase from various
biological sources produces biliverdin. Like bilirubin, biliverdin has
been shown to have these cytoprotective properties but is more soluble,
reduced toxicity and as such, reduced side effects. Thus biliverdin is
a safer alternative to bilirubin for therapeutic treatment of
cardiovascular disease, cancers, inflammation and Alzheimer's in both
human and non-human mammals.
The current technology involves methods of use and compositions of
matter for the production and collection of biliverdin from
microorganisms, including the yeast Candida albicans. Further claims
include methods to enhance biliverdin production in microorganisms and
use of biliverdin in the production of pharmaceuticals.
Vaccines Using Universally Inactivated Viruses, Parasites, and Tumor
Cells
Yossef Raviv et al. (NCI)
U.S. Provisional Application filed 22 Mar 2004 (DHHS Reference No. E-
303-2003/0-US-01)
Licensing Contact: Susan Ano; (301) 435-5515; anos@mail.nih.gov.
The current technology describes the universal inactivation of
viruses, parasites, and tumor cells by hydrophobic, photoactivatable
compounds. These non-toxic compounds, such as 1,5-iodoanpthylazide
(INA), will selectively accumulate in the innermost regions of
biological membrane bilayers, where the compounds will bind to proteins
and lipids upon irradiation with light, thus inactivating deeply
embedded proteins while maintaining integrity and activity of the
proteins on the surface. This inactivation preserves the structural and
conformational integrity and therefore immunogenicity of the agent in
question, which overcomes a potential problem associated with some
other vaccines such as those containing killed pathogens. Furthermore,
the inactivation approach presented in this technology provides for a
safe, non-infectious composition for vaccination against the
corresponding agent, whereas some vaccines, such as those involving
live-attenuated microbial agents, still have a risk of infectivity
associated with them.
Quinoline Inhibitors of Retroviral Integrase
Drs. Yves Pommier and Christophe Marchand (both of NCI); Drs. Roberto
Di Santo, Marino Artico, and Roberta Costi (all of Pharmacy University
of Rome ``La Sapienza'')
U.S. Provisional Application filed 10 Mar 2004 (DHHS Reference No. E-
187-2003/0-US-01)
Licensing Contact: Sally Hu; (301) 435-5606; hus@mail.nih.gov.
The subject invention describes certain diketo quinolin-4-1
derivatives and their use as integrase inhibitors in the treatment of
HIV infection. The results of in vitro integrase inhibition studies
show that these derivatives have significant anti-integrase activity
(e.g., an IC50 for strand transfer inhibition of not greater than 2
[mu]M). Thus, these derivatives might be potentially important lead
compounds for the development of integrase inhibitors. Since HIV
integrase is an essential enzyme for effective viral replication, the
development of such inhibitors of HIV integrase would thus potentially
be useful and effective in the treatment of HIV infection.
Dated: May 21, 2004.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 04-12127 Filed 5-27-04; 8:45 am]
BILLING CODE 4140-01-P